Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Pelthos Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Biological Products, (No Diagnostic Substances)
Prev close 27.51 · gapped below the open, never looked back. High/low 22.11 at 11:45 am ET, 21.21 at 3:45 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In addition, for the year ended December 31, 2025, these three wholesalers accounted for 89% of gross revenue at 35%, 28% and 26%, respectively.”
$6M relationship
basisPTHS fy2025 · closed 2025-12 $17M
FILING10-K0001919246-26-000013cik 0001919246
“In addition, for the year ended December 31, 2025, these three wholesalers accounted for 89% of gross revenue at 35%, 28% and 26%, respectively.”
$6M relationship
basisPTHS fy2025 · closed 2025-12 $17M
FILING10-K0001919246-26-000013cik 0001919246
“In addition, for the year ended December 31, 2025, these three wholesalers accounted for 89% of gross revenue at 35%, 28% and 26%, respectively.”
$5M relationship
basisPTHS fy2025 · closed 2025-12 $17M
FILING10-K0001919246-26-000013cik 0001919246
“In addition, for the year ended December 31, 2025, these three wholesalers accounted for 89% of gross revenue at 35%, 28% and 26%, respectively.”
$5M relationship
basisPTHS fy2025 · closed 2025-12 $17M
FILING10-K0001919246-26-000013cik 0001919246
“In addition, for the year ended December 31, 2025, these three wholesalers accounted for 89% of gross revenue at 35%, 28% and 26%, respectively.”
$4M relationship
basisPTHS fy2025 · closed 2025-12 $17M
FILING10-K0001919246-26-000013cik 0001919246
“In addition, for the year ended December 31, 2025, these three wholesalers accounted for 89% of gross revenue at 35%, 28% and 26%, respectively.”
$4M relationship
basisPTHS fy2025 · closed 2025-12 $17M
FILING10-K0001919246-26-000013cik 0001919246
“On March 24, 2025, LNHC assigned its intellectual property portfolio related to the Novan acquisition, including the NITRICIL technology, to Ligand and entered into an exclusive license and sublicense agreement with Ligand, pursuant to which Ligand licensed to the Company the intellectual property rights necessary to make, use, sell or offer to sell ZELSUVMI for the treatment of molluscum contagiosum in humans worldwide, except for Japan.”
FILING10-K0001919246-26-000013cik 0001919246
“This lease dated as of January 18, 2021, as amended (the "TBC Lease"), is by and between the Company and Copper II 2020, LLC (the "TBC Landlord"), pursuant to which the Company is leasing space serving as its corporate headquarters and primary API manufacturing site (the "Premises") located within the Triangle Business Center.”
FILING10-K0001919246-26-000013cik 0001919246
“On November 6, 2025, we acquired the U.S. commercialization rights to XEPI, from Biofrontera and an exclusive license agreement with Ferrer.”
FILING10-K0001919246-26-000013cik 0001919246
“On November 20, 2025, the Company entered into a Downpayment Agreement for XEGLYZE Assets Purchase (the "Downpayment Agreement") with Hatchtech Pty Ltd. ("Hatchtech") to purchase the right, title and interest in XEGLYZE (the "Product"), an FDA-approved Abametapir lotion treatment for head lice infestation in humans.”
FILING10-K0001919246-26-000013cik 0001919246
“Interquim will act as the supplier to the Company of XEPI in the Territory.”
FILING10-K0001919246-26-000013cik 0001919246
“In February 2025, LNHC entered into a non-exclusive Contract Management Agreement with Orion to manufacture and assemble various components related to the ZELSUVMI commercial drug product, including the final fill/finish process and product packaging.”
FILING10-K0001919246-26-000013cik 0001919246
“The UNC License Agreement currently requires the Company to pay UNC up to $250,000 in regulatory and commercial milestones on a licensed product by licensed product basis and a running royalty percentage in the low single digits on net sales of licensed products.”
FILING10-K0001919246-26-000013cik 0001919246
“This revenue is related to recognition of deferred revenue from a collaboration agreement with Sato Pharmaceutical Co., Ltd. ("Sato Agreement").”
FILING10-K0001919246-26-000013cik 0001919246
“The Company acquired the U.S. commercialization rights to XEPI, from Biofrontera, Inc. ("Biofrontera") and an exclusive license agreement with Ferrer Internacional S.A. ("Ferrer") and Interquim, S.A.U. ("Interquim").”
FILING10-K0001919246-26-000013cik 0001919246
“The Company acquired the U.S. commercialization rights to XEPI, from Biofrontera, Inc. ("Biofrontera") and an exclusive license agreement with Ferrer Internacional S.A. ("Ferrer") and Interquim, S.A.U. ("Interquim").”
FILING10-K0001919246-26-000013cik 0001919246
“The Company acquired the U.S. commercialization rights to XEPI, from Biofrontera, Inc. ("Biofrontera") and an exclusive license agreement with Ferrer Internacional S.A. ("Ferrer") and Interquim, S.A.U. ("Interquim").”
FILING10-K0001919246-26-000013cik 0001919246
“On March 24, 2025, LNHC assigned its IP portfolio related to the Novan acquisition, including the NITRICIL technology, to Ligand and entered into an exclusive license and sublicense agreement with Ligand, pursuant to which Ligand licensed to LNHC the intellectual property rights necessary to make, use, sell or offer to sell ZELSUVMI for the treatment of molluscum contagiosum in humans worldwide, except for Japan.”
FILING10-K0001919246-26-000013cik 0001919246
“The MSA between Ligand and the Company provides Ligand, Ligand affiliated parties or third-party licensees with an ability to source commercial or developmental supply of API, while also providing the Company with the associated economics of the supply of such material.”
FILING10-K0001919246-26-000013cik 0001919246
“The Company distributes ZELSUVMI via standard retail pharmacy chains, mail order pharmacies and Amazon pharmacy utilizing a third-party logistics provider.”
FILING10-K0001919246-26-000013cik 0001919246
Watchlist prices, news filtered to it, and its next report on your desk.
Pelthos Therapeutics Inc. has 11 disclosed suppliers and 9 disclosed customers. Each one is named in an SEC filing, either Pelthos Therapeutics Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
PTHS (Pelthos Therapeutics Inc.) has 11 disclosed suppliers and 9 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: AMZN −2.02%, in cloud.